Cargando…
A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management
BACKGROUND: High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-based chemotherapy, up to a quarter will be resistant to treatment. We aimed to ide...
Autores principales: | Bradbury, Melissa, Borràs, Eva, Vilar, Marta, Castellví, Josep, Sánchez-Iglesias, José Luis, Pérez-Benavente, Assumpció, Gil-Moreno, Antonio, Santamaria, Anna, Sabidó, Eduard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773449/ https://www.ncbi.nlm.nih.gov/pubmed/36544142 http://dx.doi.org/10.1186/s12967-022-03816-7 |
Ejemplares similares
-
BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling
por: Bradbury, Melissa, et al.
Publicado: (2022) -
Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review
por: Bradbury, Melissa, et al.
Publicado: (2021) -
Ovarian Fibrosarcoma: Clinicopathologic Considerations about the Intraoperative and Post-Surgical Procedures
por: García Jiménez, Angel, et al.
Publicado: (2009) -
Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018) -
Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer
por: Parrilla, Alfonso, et al.
Publicado: (2020)